New Topical Vectra 3D™ Provides Dogs Long-Lasting Protection from Fleas, Ticks and Mosquitoes

Dinotefuran, Pyriproxyfen, Permethrin Combination Delivers Faster, Effective and More Complete Relief for Dogs

September 12, 2007, Fort Lee, N.J. – Summit VetPharm today announced the introduction of Vectra 3DTM, a new broad-spectrum topical that effectively protects dogs against three vectors – fleas, ticks, and mosquitoes. The company’s studies show that Vectra 3D delivers efficacy of at least 30 days for a wide range of parasites.

The chronic nature of flea and tick control contributes to the potential for resistant fleas and ectoparasites. The introduction of Vectra 3D with Dinotefuran, a new third- generation neonicotinoid will help combat resistance.

“Ectoparasites have never been exposed to this new molecule,” said Dr. Albert H. Ahn, DVM, senior director of veterinary services for Summit VetPharm. “Our studies show that Vectra 3D is as effective on day 30 as it is on day one.”

Vectra 3D’s new insecticide is colorless, odor free, non-greasy, quick-drying and water- resistant. In studies conducted both in the laboratory and in the field, Vectra 3D has shown no clinically significant treatment-related adverse events, and has a rapid knockdown effect. “Vectra 3D has demonstrated remarkable speed of kill and reinfestation protection in all weight ranges of dogs,” according to Ahn.

Vectra 3D kills 96 percent of fleas within six hours, repels other fleas from attaching to the dog and prevents development of flea eggs, larvae and pupae. “Pet owners want fleas killed as quickly as possible to end their dogs’ suffering,” Ahn says. “Oftentimes, the successive feeding activity of fleas on dogs elicits a hypersensitivity skin disorder known as flea allergy dermatitis (FAD). Treatment of dogs with Vectra 3D rapidly kills fleas and may reduce further evidence of FAD.”

Vectra 3D repels and kills four species of ticks (deer tick, brown dog tick, American dog tick and Gulf Coast tick) and three species of mosquitoes (Culex, Ochlerotatus and Aedes). “With the increased threat of vector borne diseases, the ability to kill and repel these parasites is extremely important. Vectra 3D kills the vectors that can cause Lyme disease, Rocky Mountain spotted fever, babesiosis, ehrlichiosis, bartonellosis, hepatozoonosis, tapeworm and heartworm disease,” explains Ahn.

Vectra 3D features a combination of new and proven ingredients that provide faster, longer and more complete relief for dogs. The triple-action formula includes:

  • Dinotefuran – a new, fast-acting, third generation neonicotinoid with a novel mode of action.
  • Permethrin – a proven, broad-spectrum molecule that works with dinotefuran to repel and kill fleas, ticks and mosquitoes.
  • Pyriproxyfen – a superior growth regulator (IGR) that prevents development at all flea stages including eggs, pupae and larvae.

“As a veterinarian, I know that the current spot-on ectoparasiticidal products have set the standard for efficacy. Summit VetPharm is building and improving upon this achievement with the launch of the Vectra 3D product,” said Ahn. “Vectra 3D will be the first product on the market that effectively eliminates three types of parasites with the total protection of a flea IGR. The added bonus is that it works for at least a month and is gentle enough for puppies seven weeks of age.”

Vectra 3D also includes major improvements for dog owners. The unique, patented applicator features an elongated tip that makes it easy to apply to a dog’s skin through the haircoat. The rounded tip minimizes risk of skin abrasions. The easy-to-open applicator eliminates splash back and spilling, and the contoured shape makes it easier to handle. With the one-piece applicator, there is no need to use scissors to open or remove a cap, making application fast and efficient and at the same time, minimizing the potential of a choking hazard.

Vectra 3D is protected with Summit VetPharm’s new Bloodhound™ Technology - an innovative, proprietary track and trace system developed by Nutec Systems that ensures veterinary exclusivity of the product. Each package of Vectra 3D can be traced from the point of manufacture to veterinary purchase. Bloodhound Technology will allow Summit VetPharm to maintain the integrity of its products through a secure distribution channel, as well as, guarding against counterfeiting.

“By securing our supply chain, we are able to protect the veterinary professional, maintain authenticity of our products, and enhance the role of veterinarians in the lives of the animals they treat. Through our Bloodhound Technology, we can help keep companion animal health exactly where it belongs — in the hands of professionals,” states Julia Stephanus, president of Summit VetPharm.

Vectra 3D’s new triple-action topical parasite formula is available to pet owners only through licensed veterinarians.

Vectra 3D is available in four different sizes: for dogs and puppies over 7 weeks of age weighing 2.5 to 20 pounds; 21 to 55 pounds; 56 to 95 pounds, and for dogs over 95 pounds.

Summit VetPharm recently announced a co-promotion agreement with Abbott Animal Health. This new partnership will strengthen Summit VetPharm's contributions to veterinarian-client-patient care by combining the innovative products and commercial expertise of Summit with the sales capability and reach of Abbott Animal Health.

Vectra 3D is currently available to veterinarians from the following distributors: NLS Animal Health, a division of Henry Schein Inc, Midwest Veterinary Supply, Inc., Merritt Veterinary Supplies, Inc., and Victor Medical Company, Hawaii Mega-Cor and Sanum Puerto Rico, Inc.

About Ceva Animal Health: Ceva’s key companion animal products include the Vectra® line of parasiticides, D.A.P.® and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets.  Ceva Biomune’s key poultry products include CEVAC® Transmune IBD, Vectormune® FP and Vectormune® HVT.  Ceva Biomune Campus and the North America Zone headquarters are both located in Lenexa, Kansas.  Visit www.ceva.us.

About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry.  Its headquarters is in Libourne, France. Visit www.ceva.com.

For more information, please contact Carolyn Gilliland at carolyn.gilliland[at]ceva.com or 913.945.4448.

###

Back to top